Subconjunctival bevacizumab for iris neovascularisation - Authors' reply

Rajesh C. Rao, Netan Choudhry, Rajendra S. Apte

Research output: Contribution to journal › Letter

Original language	English
Pages (from-to)	450-451
Number of pages	2
Journal	The Lancet Diabetes and Endocrinology
Volume	2
Issue number	6
DOIs	https://doi.org/10.1016/S2213-8587(14)70071-3
State	Published - Jun 2014

Cite this

@article{4f1f652be32f4e7e97535ff943d7ec11,

title = "Subconjunctival bevacizumab for iris neovascularisation - Authors' reply",

author = "Rao, {Rajesh C.} and Netan Choudhry and Apte, {Rajendra S.}",

year = "2014",

month = jun,

doi = "10.1016/S2213-8587(14)70071-3",

language = "English",

volume = "2",

pages = "450--451",

journal = "The Lancet Diabetes and Endocrinology",

issn = "2213-8587",

number = "6",

}

TY - JOUR

T1 - Subconjunctival bevacizumab for iris neovascularisation - Authors' reply

AU - Rao, Rajesh C.

AU - Choudhry, Netan

AU - Apte, Rajendra S.

PY - 2014/6

Y1 - 2014/6

UR - http://www.scopus.com/inward/record.url?scp=84901428194&partnerID=8YFLogxK

U2 - 10.1016/S2213-8587(14)70071-3

DO - 10.1016/S2213-8587(14)70071-3

M3 - Letter

C2 - 24880562

AN - SCOPUS:84901428194

VL - 2

SP - 450

EP - 451

JO - The Lancet Diabetes and Endocrinology

JF - The Lancet Diabetes and Endocrinology

SN - 2213-8587

IS - 6

ER -